Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/13/2025

Extramedullary Hematopoiesis in Myeloid Sarcoma and Other Hematologic Disorders

Clinical Manifestations and Diagnostic Features

  • The presence of myeloid sarcoma, a distinct manifestation of extramedullary acute myeloid leukemia (AML), requires systemic AML-directed chemotherapy, not just local treatment, as recommended by the American Society of Hematology 1, 2
  • Myeloid sarcoma is distinguished from frank AML by less than 20% bone marrow blasts, according to the World Health Organization classification 1, 2
  • Extramedullary hematopoiesis (EMH) can be misdiagnosed as lymphoma, particularly non-Hodgkin lymphoma, especially when occurring in lymph nodes or as mass lesions, highlighting the importance of accurate diagnosis by the International Society of Hematopathology 1, 2

Pathologic EMH and Underlying Conditions

  • Clinical complications from mass effect, such as organomegaly, organ dysfunction, pleural effusions, and ascites, can occur in patients with pathologic EMH, as reported by the European Hematology Association 1
  • Tumor-induced EMH contributes to immunosuppression in advanced malignancies, according to the National Comprehensive Cancer Network 3
  • In plasma cell disorders, disruption of adhesion molecules facilitates extramedullary spread and disease dissemination, as noted by the International Myeloma Society 3

Special Considerations in Specific Diseases

  • Leukemic blasts in transient leukemia and myeloid leukemia of Down syndrome originate from fetal liver hematopoiesis, highlighting the importance of understanding the underlying biology of these disorders, as recommended by the American Academy of Pediatrics 1, 2
  • Splenomegaly from EMH is a major clinical feature requiring specific management approaches in patients with myelofibrosis, according to the European Society of Medical Oncology 4

Leukemic Infiltration of Soft Tissue

Overview of Extramedullary Leukemic Infiltration

  • Leukemic cells can infiltrate virtually any extramedullary site, including soft tissues of the extremities, though this occurs less frequently than involvement of lymph nodes, skin, and bones, as noted by the American Society of Hematology 5
  • Myeloid sarcoma is the most well-characterized form of soft tissue leukemic infiltration, occurring in 5-7% of patients with acute myeloid leukemia (AML), and most commonly involves skin, lymph nodes, gastrointestinal tract, bone, and soft tissue 5, 6

Diagnostic Approach

  • The American Society of Hematology recommends considering soft tissue leukemic infiltration in any patient with known leukemia who develops new focal pain, swelling, or mass in an extremity, muscle weakness localized to a specific region, or palpable soft tissue masses 7
  • Imaging studies, including MRI and CT, are essential for characterizing soft tissue masses and assessing enhancement patterns, as noted by the National Comprehensive Cancer Network 7, 8
  • Tissue biopsy with proper specimen handling, including immunohistochemistry and flow cytometry, is crucial for definitive diagnosis of soft tissue leukemic infiltration 5, 8

Treatment Implications

  • The American Society of Hematology recommends systemic chemotherapy directed at the underlying leukemia for any soft tissue leukemic infiltration, as local treatment alone is inadequate 8
  • The presence of extramedullary disease may indicate more aggressive disease requiring intensified therapy, as noted by the National Comprehensive Cancer Network 8
  • The American Society of Hematology recommends that decreasing joint or soft tissue pain is often the first sign of clinical response to chemotherapy 9